Menu
Search
|

Menu

Close
X

Coherus BioSciences Inc CHRS.OQ (NASDAQ Stock Exchange Global Market)

17.90 USD
-- (--)
As of Jul 18
chart
Previous Close 17.90
Open --
Volume --
3m Avg Volume 189,518
Today’s High --
Today’s Low --
52 Week High 18.10
52 Week Low 8.07
Shares Outstanding (mil) 65.33
Market Capitalization (mil) 973.37
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
2
FY16
190
FY15
30
EPS (USD)
FY18
-0.737
FY17
-1.425
FY16
-3.476
FY15
-5.982
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.89
Price to Sales (TTM)
vs sector
697.75
8.00
Price to Book (MRQ)
vs sector
--
4.21
Price to Cash Flow (TTM)
vs sector
--
22.15
Total Debt to Equity (MRQ)
vs sector
--
17.41
LT Debt to Equity (MRQ)
vs sector
--
13.26
Return on Investment (TTM)
vs sector
-18.02
13.14
Return on Equity (TTM)
vs sector
-66.69
15.15

EXECUTIVE LEADERSHIP

Dennis Lanfear
Chairman of the Board, President, Chief Executive Officer, Since 2016
Salary: $652,609.00
Bonus: $469,020.00
Jean-Frederic Viret
Chief Financial Officer, Since 2014
Salary: $389,166.00
Bonus: $158,758.00
Peter Watler
Chief Technology Officer, Since 2014
Salary: $365,378.00
Bonus: $147,035.00
Alan Herman
Chief Scientific Officer, Since 2011
Salary: $311,822.00
Bonus: $40,688.00
Vincent Anicetti
Chief Quality and Compliance Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

333 Twin Dolphin Dr Ste 600
REDWOOD CITY   CA   94065-1442

Phone: +1650.6493530

Coherus BioSciences, Inc. is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company's business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131. The Company's product candidate pipeline includes CHS-1701, CHS-5217, CHS-0214, CHS-1420 and CHS-3351. Its CHS-1701 is a Granulocyte colony-stimulating factor (G-CSF) product candidate. Its Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Its Etanercept (Enbrel) is the reference product for CHS-0214.

SPONSORED STORIES